OMED Health ("OMED"), part of Owlstone Medical ("Owlstone"), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, and Welbeck Health Partners ("Welbeck"), one of the UK's largest specialist outpatient healthcare providers, today announced that Welbeck has adopted OMED Health's home-based Small Intestinal Bacterial Overgrowth (SIBO) breath-testing pathway. The roll out across Welbeck's network follows a three-month evaluation where the pathway was assessed for performance and impact on standard of care.